Michael A Jakupec Selected Research

Metals

1/2022	Systematic Study on the Cytotoxic Potency of Commonly Used Dimeric Metal Precursors in Human Cancer Cell Lines.
4/2016	Behavior of platinum(iv) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation.
4/2016	LA-ICP-MS imaging in multicellular tumor spheroids - a novel tool in the preclinical development of metal-based anticancer drugs.
1/2016	Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines.
12/2012	A SAR study of novel antiproliferative ruthenium and osmium complexes with quinoxalinone ligands in human cancer cell lines.
8/2010	Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy.
11/2009	Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
1/2009	Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells.
11/2007	Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones.
1/2004	Gallium and other main group metal compounds as antitumor agents.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael A Jakupec Research Topics

Disease

85	Neoplasms (Cancer) 03/2024 - 01/2002
25	Carcinoma (Carcinomatosis) 11/2022 - 01/2005
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2020 - 08/2008
7	Colorectal Neoplasms (Colorectal Cancer) 02/2024 - 01/2004
7	Colonic Neoplasms (Colon Cancer) 01/2021 - 01/2004
6	Teratocarcinoma 03/2023 - 12/2015
3	Ovarian Neoplasms (Ovarian Cancer) 07/2015 - 01/2004
2	Lymphoma (Lymphomas) 12/2022 - 01/2004
2	Leukemia 12/2022 - 12/2021
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2022 - 01/2004
2	Neoplasm Metastasis (Metastasis) 12/2021 - 08/2015
2	Leukemia L1210 01/2017 - 01/2014
1	Inflammation (Inflammations) 09/2023
1	Hypersensitivity (Allergy) 12/2021
1	Breast Neoplasms (Breast Cancer) 01/2020
1	Hypoxia (Hypoxemia) 04/2016
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2016

Drug/Important Bio-Agent (IBA)

24	Cisplatin (Platino)FDA LinkGeneric 09/2023 - 01/2005
20	PlatinumIBA 05/2023 - 01/2004
20	RutheniumIBA 01/2022 - 08/2005
17	LigandsIBA 03/2024 - 01/2004
13	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2023 - 01/2004
10	MetalsIBA 01/2022 - 01/2004
9	GalliumIBA 12/2022 - 01/2002
8	OsmiumIBA 01/2022 - 08/2008
6	DNA (Deoxyribonucleic Acid)IBA 11/2023 - 08/2010
5	IndazolesIBA 01/2019 - 05/2007
5	indazolium trans- (tetrachlorobis(1H- indazole)ruthenate (III))IBA 07/2014 - 08/2005
5	4-cymene (p-cymene)IBA 07/2013 - 05/2009
4	Proteins (Proteins, Gene)FDA Link 12/2019 - 12/2009
4	diphenyl (biphenyl)IBA 03/2013 - 10/2008
3	IronIBA 01/2024 - 01/2004
3	Antineoplastic Agents (Antineoplastics)IBA 12/2021 - 11/2006
3	KP 1339IBA 08/2021 - 08/2015
3	SodiumIBA 01/2019 - 06/2015
3	ProdrugsIBA 09/2017 - 07/2015
3	Coordination ComplexesIBA 08/2016 - 01/2009
3	CationsIBA 11/2009 - 01/2004
2	IridiumIBA 01/2022 - 01/2020
2	RhodiumIBA 01/2022 - 01/2020
2	IsotopesIBA 01/2021 - 06/2014
2	3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA 03/2014 - 01/2010
2	CopperIBA 11/2013 - 09/2012
2	paulloneIBA 11/2013 - 09/2012
2	QuinolinesIBA 09/2013 - 08/2010
2	CymenesIBA 03/2013 - 11/2009
2	Transferrin (beta 2 Transferrin)IBA 02/2013 - 11/2006
2	BenzazepinesIBA 12/2011 - 08/2010
2	BromidesIBA 10/2009 - 12/2008
2	Ruthenium CompoundsIBA 08/2008 - 06/2007
2	tris(8-quinolinolato)gallium (III)IBA 11/2006 - 01/2004
2	Transferrin Receptors (Transferrin Receptor)IBA 01/2004 - 01/2004
2	gallium nitrate FDA Link 01/2004 - 01/2004
2	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 01/2004 - 01/2004
1	MicroplasticsIBA 02/2024
1	Polystyrenes (Polystyrene)IBA 02/2024
1	VLX600IBA 01/2024
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 09/2023
1	PAMAM StarburstIBA 05/2023
1	Dendrimers (Dendrons)IBA 05/2023
1	Protective AgentsIBA 12/2022
1	Vincristine (Oncovin)FDA LinkGeneric 12/2022
1	Daunorubicin (Cerubidine)FDA LinkGeneric 12/2022
1	quinone (benzoquinone)IBA 11/2022
1	phthiocolIBA 11/2022
1	Oxidoreductases (Dehydrogenase)IBA 11/2022
1	NAD (NADH)IBA 11/2022
1	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2022
1	ApatitesIBA 12/2021
1	Diphosphonates (Bisphosphonates)IBA 12/2021
1	Therapeutic UsesIBA 01/2021
1	ElementsIBA 01/2021
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 01/2021
1	polyanionsIBA 03/2020
1	EnzymesIBA 01/2020
1	3-hydroxy-2-methyl-4H-pyran-4-thioneIBA 01/2020
1	Adenosine Triphosphate (ATP)IBA 01/2019
1	CalreticulinIBA 01/2019
1	PlectinIBA 01/2017
1	SolutionsIBA 11/2016
1	Platinum Compounds (Compounds, Platinum)IBA 04/2016
1	FlavonoidsIBA 01/2016
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 01/2016
1	diacetyldichlorofluoresceinIBA 01/2016
1	NKP-1339IBA 01/2016
1	LanthanumIBA 08/2015
1	acetyl acetonate (acetylacetonate)IBA 06/2015
1	VanadiumIBA 06/2015
1	Vanadates (Orthovanadate)IBA 06/2015
1	phosphoramidic acidIBA 07/2014
1	Activating Transcription FactorsIBA 03/2014
1	1,2-cyclohexanediamine (dach)IBA 01/2014
1	TEMPOIBA 11/2013
1	Peptides (Polypeptides)IBA 07/2013

Therapy/Procedure

7	Therapeutics 12/2022 - 01/2004
4	Drug Therapy (Chemotherapy) 03/2018 - 01/2004
2	Aftercare (After-Treatment) 01/2017 - 04/2015
1	Laser Therapy (Surgery, Laser) 11/2020
1	Oral Administration 01/2017
1	Lasers (Laser) 06/2014